Table 3.
PK Parameter | Method | Ratio (%) | 90% CI (%) | ANOVA-CV (%) |
AUCτ | MWW-log* | 89.2 | 82.5–96.2 | 23.3 |
Cmax, ss | MWW-log* | 97.5 | 91.1–104.5 | 19.5 |
Ctrough | ANOVA-log | 103.8 | 94.0–114.6 | 26.4 |
t1/2 | MWW-log* | 87.8 | 75.3–100.0 | 41.4 |
AUCτ = area under total concentration curve from 0–36 h at steady state; Cmax, ss = peak serum concentration at steady state; Ctrough = mean pre-dose trough concentration on day 24; t1/2 = terminal elimination half-life; ANOVA-CV = ANOVA coefficient of variation; Method = method used to calculate 90% CI (ANOVA or Mann-Whitney-Wilcoxon of log-transformed data). *Significant deviation of the ANOVA residuals from normal distribution p < 0.05. The treatments were considered bioequivalent if the ratio and 90% CI fell within the range of 80–125%.